BIOKIN PHARMACEUTICAL(SH:688506) Shang Hai Zheng Quan Bao·2025-10-09 18:39Group 1 - The A-share market is experiencing a steady upward trend, with increased participation from public funds in the private placement market, totaling over 30 billion yuan this year, surpassing the total for the entire previous year [1] - A total of 34 fund companies have participated in private placements this year, with a cumulative subscription amount of 30.12 billion yuan as of October 9, 2023 [1] - Notable fund companies such as Nord Fund and Caitong Fund have each subscribed over 8 billion yuan, while others like E Fund and GF Fund have also shown significant participation [1] Group 2 - Caitong Fund indicates that the supply in the private placement market has been stable with increased enthusiasm from funds, reflecting a positive outlook for the performance of private placement assets [2] - Well-known fund managers are actively participating in private placements, particularly in high-end manufacturing and pharmaceutical sectors [2] - For instance, Guo Lan's fund subscribed for shares in the innovative drug company Baili Tianheng, with a total investment of 588 million yuan, representing 1.8% of the fund's net asset value [2] Group 3 - Other funds managed by Yang Ruiwen and Liu Xu have also participated in private placements for leading companies in the photovoltaic sector and technology sector, respectively [3] - Specific funds like E Fund's New Income Mixed Fund and E Fund's Secure Return Bond Fund have engaged in private placements for TCL Technology [3]